Read by QxMD icon Read

Nephrology Now

shared collection
12 papers 0 to 25 followers
Rajni Singhal, Janet E Hux, Shabbir M H Alibhai, Matthew J Oliver
Adequacy of chronic kidney disease (CKD) care is traditionally measured as early or late, but this does not reflect the effect of cumulative or consistent care. Here we relate alternate measures of CKD care to mortality and other outcomes in patients with end-stage renal disease (ESRD) who started renal replacement therapy (RRT) between 1998 and 2008. CKD care was defined traditionally as early or late, and alternatively as cumulative care (total visits) and consistency of care in the critical period immediately prior to start of RRT (consistent critical period care required visits in 3 or more of the 6 months prior to RRT start)...
August 2014: Kidney International
Christoph Wanner, Marcello Tonelli
The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines on lipid management for all adults and children with chronic kidney disease (CKD). Thirteen recommendations were obtained from the available evidence outlining a three-step management including assessment in all, treatment in many, and follow-up measurements in few. A key element is the recommendation of statin or statin/ezetimibe treatment in adults aged ⩾50 years with estimated glomerular filtration rate (eGFR) <60 ml/min per 1...
June 2014: Kidney International
Rajiv Agarwal, Arjun D Sinha, Maria K Pappas, Terri N Abraham, Getachew G Tegegne
BACKGROUND: The purpose of this study was to determine among maintenance hemodialysis patients with echocardiographic left ventricular hypertrophy and hypertension whether in comparison with a β-blocker-based antihypertensive therapy, an angiotensin converting enzyme-inhibitor-based antihypertensive therapy causes a greater regression of left ventricular hypertrophy. METHODS: Subjects were randomly assigned to either open-label lisinopril (n = 100) or atenolol (n = 100) each administered three times per week after dialysis...
March 2014: Nephrology, Dialysis, Transplantation
Chen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, Chia-Yen Dai, Cheng-Chao Liang, Jee-Fu Huang, Peir-Haur Hung, Hung-Bin Tsai, Meng-Kun Tsai, Shih-I Chen, Jou-Wei Lin, Sheng-Shun Yang, Tung-Hung Su, Hung-Chih Yang, Pei-Jer Chen, Ding-Shinn Chen, Wan-Long Chuang, Ming-Lung Yu, Jia-Horng Kao
BACKGROUND: Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. OBJECTIVE: To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and pegylated interferon monotherapy for treatment-naive patients with HCV-1 receiving hemodialysis. DESIGN: Open-label, randomized, controlled trial...
December 3, 2013: Annals of Internal Medicine
Ulrich Specks, Peter A Merkel, Philip Seo, Robert Spiera, Carol A Langford, Gary S Hoffman, Cees G M Kallenberg, E William St Clair, Barri J Fessler, Linna Ding, Lisa Viviano, Nadia K Tchao, Deborah J Phippard, Adam L Asare, Noha Lim, David Ikle, Brett Jepson, Paul Brunetta, Nancy B Allen, Fernando C Fervenza, Duvuru Geetha, Karina Keogh, Eugene Y Kissin, Paul A Monach, Tobias Peikert, Coen Stegeman, Steven R Ytterberg, Mark Mueller, Lourdes P Sejismundo, Kathleen Mieras, John H Stone
BACKGROUND: The 18-month efficacy of a single course of rituximab as compared with conventional immunosuppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown. METHODS: In a multicenter, randomized, double-blind, double-dummy, noninferiority trial, we compared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks) followed by placebo with cyclophosphamide administered for 3 to 6 months followed by azathioprine for 12 to 15 months...
August 1, 2013: New England Journal of Medicine
Sophie A Jamal, Ben Vandermeer, Paolo Raggi, David C Mendelssohn, Trish Chatterley, Marlene Dorgan, Charmaine E Lok, David Fitchett, Ross T Tsuyuki
BACKGROUND: Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphataemia in patients with chronic kidney disease, but their effects on mortality and cardiovascular outcomes are unknown. We aimed to update our meta-analysis on the effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease. METHODS: We did a systematic review of articles published in any language after Aug 1, 2008, up until Oct 22, 2012, by searching Medline, Embase, International Pharmaceutical Abstracts, Cochrane Central Register of Controlled Trials, and Cumulative Index to Nursing and Allied Health Literature...
October 12, 2013: Lancet
Brian L Strom, Cheryl A M Anderson, Joachim H Ix
No abstract text is available yet for this article.
July 3, 2013: JAMA: the Journal of the American Medical Association
Gearoid M McMahon, Sushrut S Waikar
No abstract text is available yet for this article.
July 2013: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Yong Li, Anna Köttgen
No abstract text is available yet for this article.
May 2013: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
Enrique Morales, Victor Gutiérrez Millet, Jorge Rojas-Rivera, Ana Huerta, Eduardo Gutiérrez, Elena Gutiérrez-Solís, Jesús Egido, Manuel Praga
BACKGROUND: Several studies have demonstrated a short-term antiproteinuric effect of mineralocorticoid receptor blockers (MRB) on proteinuric kidney diseases, but no information is available about the long-term persistence (>1 year) of such reduction in proteinuria and the long-term effects of MRB on renal function. METHODS: We prospectively studied the effects of adding spironolactone (25 mg/day) to 87 patients who maintained proteinuria higher than 1 g/day in spite of renin-angiotensin system blockade...
February 2013: Nephrology, Dialysis, Transplantation
Tracy Minichiello
No abstract text is available yet for this article.
December 10, 2012: Archives of Internal Medicine
Karen L Margolis, Tessa J Kerby, Stephen E Asche, Anna R Bergdall, Michael V Maciosek, Patrick J O'Connor, JoAnn M Sperl-Hillen
BACKGROUND: Patients with high blood pressure (BP) visit a physician an average of 4 times or more per year in the U.S., yet BP is controlled in fewer than half. Practical, robust and sustainable models are needed to improve BP in patients with uncontrolled hypertension. OBJECTIVES: The Home Blood Pressure Telemonitoring and Case Management to Control Hypertension study (HyperLink) is a cluster-randomized trial designed to determine whether an intervention that combines home BP telemonitoring with pharmacist case management improves BP control compared to usual care at 6 and 12 months in patients with uncontrolled hypertension...
July 2012: Contemporary Clinical Trials
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"